

Serial No.: 10/802,273

RECEIVED  
CENTRAL FAX CENTER 31162B

OCT 31 2007

AMENDMENTIN THE CLAIMS

Please amend the claims as follows:

1. (Previously amended) A hormonal regimen comprising daily sequential dosages wherein at least one of the daily dosages comprises at least 0.5 mg of norgestimate and an estrogen component in the range of at least 20 to less than 35 mcg Ethinyl Estradiol (EE) equivalent.
2. (Previously amended) The regimen of claim 1 wherein said at least one daily dosage has 0.5 - 0.8 mg of norgestimate.
3. (Previously amended) The regimen of claim 1 wherein said at least one daily dosage has at least 0.8 mg of norgestimate.
4. (Previously amended) The regimen of claim 3 wherein the said at least one daily dosage has 0.8 - 1.2 mg of norgestimate.
5. (Previously amended) The regimen of claim 2 wherein said at least one daily dosage has at least 1.0 mg of norgestimate.
6. (Previously amended) The regimen of claim 5 wherein the said at least one daily dosage has 1.0 - 2.0 mg of norgestimate.
7. (Previously amended) A hormonal regimen comprising daily sequential dosages wherein at least one of the daily dosages comprises at least 1.2 mg of norgestimate and an estrogen component in the range of 20-35 mcg Ethinyl Estradiol (EE) equivalent.
8. (Previously amended) The regimen of claim 7 wherein said at least one daily dosage has at least 1.8 mg of norgestimate.
9. (Previously amended) The regimen of claim 7 wherein said at least one daily dosage has at least 2.5 mg of norgestimate.

Serial No.: 10/802,273

31162B

10. (Previously amended) The regimen of claim 2 wherein said at least one daily dosage has 0.5 mg of norgestimate.

11. (Previously amended) The regimen of claim 4 wherein said at least one daily dosage is has 0.8 mg of norgestimate.

12. (Previously amended) The regimen of claim 1 wherein said estrogen component of said at least one daily dosage does not exceed 25 mcg ethinyl estradiol equivalent.

13. (Previously amended) The regimen of claim 1 wherein said estrogen component of said at least one daily dosage is ethinyl estradiol.

14. (Previously amended) The regimen of claim 1 wherein said estrogen component of said at least one daily dosage is 20 mcg ethinyl estradiol.

15. (Previously amended) The regimen of claim 1 wherein said regimen is multi-phasic, with one phase having a daily dosage of norgestimate of at least 0.5 mg.

16. (Previously amended) A hormonal regimen comprising daily sequential dosages wherein at least one of the daily dosages comprises at least 0.5 mg of norgestimate and an estrogen component in the range of 20-35 mcg Ethinyl Estradiol (EE) equivalent, and wherein said regimen is multi-phasic, with one phase having a daily dosage of norgestimate of at least 0.8 mg and another phase having daily dosage of norgestimate of 0.2-0.3 mg.

17. (Previously amended) The regimen of claim 1 wherein said regimen consists of a 21-28 daily dosages for a cycle, and wherein the total norgestimate in said cycle is at least 8 mg.

18. (Previously presented) The regimen of claim 17 wherein said total norgestimate in said cycle is at least 12 mg.

19. (Previously amended) The regimen of claim 7 wherein said total norgestimate in said cycle is at least 20 mg.

Serial No.: 10/802,273

31162B

20. (Previously presented) The regimen of claim 15 wherein another phase has and a daily dosage of norgestimate of 0.18-0.25 mg.

21. (Previously presented) The regimen of claim 15 wherein said regimen has another phase with a daily dosage of norgestimate of 0.18 mg.

22. (Currently amended) The regimen of claim 23 wherein said [regimen has] another phase [with] has a daily dosage of norgestimate of 0.215 mg.

23. (Previously amended) A hormonal regimen comprising daily sequential dosages wherein at least one of the daily dosages comprises at least 0.5 mg of norgestimate and an estrogen component in the range of 20-35 mcg Ethinyl Estradiol (EE) equivalent, wherein said regimen is multi-phasic, with one phase having a daily dosage of norgestimate of at least 0.5 mg and has another phase with a daily dosage of norgestimate of 0.2-0.3 mg.

24. (Previously presented) The regimen of claim 1 wherein said regimen consists of a 20-35 daily dosages for a cycle, and wherein the total norgestimate in said cycle is at least 8 mg.

25. (Cancelled)

26. (Cancelled)